ASH 2020 | Updates on daratumumab use in myeloma at ASH 2020
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, shares key updates to look out for at ASH 2020 surrounding the use of daratumumab in multiple myeloma. Daratumumab is an anti-CD38 monoclonal antibody that targets tumor cells via both direct apoptotic action and immunomodulatory mechanisms. There will be numerous abstracts presented on its use in myeloma populations. These include: an update of the GRIFFIN trial (NCT02874742) of daratumumab in combination with lenalidomide, bortezomib and dexamethasone as induction, consolidation and maintenance therapy; updated follow-up results for the Phase III MAIA study (NCT02252172); and analysis of sustained MRD-negativity in the MAIA and ALCYONE (NCT02195479) trials. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
